Uso de recursos y costes asociados a las exacerbaciones de enfermedad pulmonar obstructiva crónica: estudio retrospectivo de base poblacional

Rabe, 2007, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, Am J Respir Crit Care Med, 176, 532, 10.1164/rccm.200703-456SO Rycroft, 2012, Epidemiology of chronic obstructive pulmonary disease: A literature review, Int J Chron Obstruct Pulmon Dis, 7, 457, 10.2147/COPD.S32330 Miravitlles, 2009, Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities, Thorax, 64, 863, 10.1136/thx.2009.115725 Burge, 2003, COPD exacerbations: Definitions and classifications, Eur Respir J, 21, 46s, 10.1183/09031936.03.00078002 Schermer, 2006, Exacerbations and associated healthcare cost in patients with COPD in general practice, Monaldi Arch Chest Dis, 65, 133 Hurst, 2010, Susceptibility to exacerbation in chronic obstructive pulmonary disease, N Engl J Med, 363, 1128, 10.1056/NEJMoa0909883 Donaldson, 2002, Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease, Thorax, 57, 847, 10.1136/thorax.57.10.847 Donaldson, 2005, Exacerbations and time spent outdoors in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 171, 446, 10.1164/rccm.200408-1054OC Arnedillo, 2012, Consenso sobre atención integral de las agudizaciones de la enfermedad pulmonar obstructiva crónica (ATINA-EPOC), Semergen, 38, 388, 10.1016/j.semerg.2012.04.001 Soler-Cataluna, 2005, Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease, Thorax, 60, 925, 10.1136/thx.2005.040527 Zalacain, 2002, Importancia de las agudizaciones de EPOC. Repercusión económica, Semergen, 28, 615, 10.1016/S1138-3593(02)74137-3 Jahnz-Rózyk, 2009, Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007 — results of multicenter Polish study, Pol Merkur Lekarski, 26, 208 Simoens, 2007, Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease, Expert Opin Pharmacother, 8, 633, 10.1517/14656566.8.5.633 Subdirección General de Información Sanitaria e Innovación. Unidad técnica de la CIAP del SNS. Extensiones de la Clasificación Internacional de Atención Primaria - versión 2 (CIPA-2). Ministerio de Sanidad, Servicios Sociales e Igualdad. Madrid, 2012 [consultado 26 Jun 2012]. Disponible en: http://www.msssi.es/estadEstudios/estadisticas/estadisticas/estMinisterio/siap.htm Manual de codificación CIE9MC. Instituto de Información Sanitaria. Ministerio de Sanidad, Política Social e Igualdad. Madrid 2011 [consultado 26 Jun 2012]. Disponible en: http://www.msc.es/estadEstudios/estadisticas/docs/Manual_de_codificacion.pdf Rodriguez-Roisin, 2000, Toward a consensus definition for COPD exacerbations, Chest, 117, 398S, 10.1378/chest.117.5_suppl_2.398S Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8 Weiner, 1991, Development and application of a population-oriented measure of ambulatory care case-mix, Med Care, 29, 452, 10.1097/00005650-199105000-00006 2012 Instituto Nacional de Estadística 2010. Encuesta de costes laborales del año 2010 [consultado Jun 2012]. Disponible en: http://www.ine.es/infoine Thompson, 2000, How should cost data in pragmatic randomized trials be analyzed?, BMJ, 320, 1197, 10.1136/bmj.320.7243.1197 Miravitlles, 2000, Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: A multiple logistic regression analysis, Respiration, 67, 495, 10.1159/000067462 Oostenbrink, 2004, Resource use and risk factors in high-cost exacerbations of COPD, Respir Med, 98, 883, 10.1016/j.rmed.2004.02.013 Llor, 2006, Factores de riesgo de elevado costes de las agudizaciones de la bronquitis crónica y EPOC, Arch Bronconeumol, 42, 175, 10.1157/13086623 Miravitlles, 2008, Tratamiento antimicrobiano de la agudización de EPOC: documento de consenso 2007, Semergen, 34, 66, 10.1016/S1138-3593(08)71852-5 Geitona, 2011, The cost of COPD exacerbations: A university hospital-based study in Greece, Resp Med, 105, 402, 10.1016/j.rmed.2010.09.020 Andersson, 2002, The costs of exacerbations in COPD, Resp Med, 96, 700, 10.1053/rmed.2002.1334 Janhz-Rozyk, 2008, Comparison of outpatient and inpatient cost of moderate and severe exacerbations of chronic pulmonary obstructive disease in Poland, Pol Penumol Allergol, 76, 426 Miravitlles, 2002, Pharmacoeconomic evaluation of acute excerbations of chronic bronchitis and COPD, Chest, 121, 1449, 10.1378/chest.121.5.1449 Masa, 2004, Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional, Arch Bronconeumol, 40, 72, 10.1016/S0300-2896(04)75476-9 Langsetmo, 2008, Underreporting exacerbations of chronic obstructive pulmonary disease in a longitudinal cohort, Am J Resp Crit Care Med, 177, 396, 10.1164/rccm.200708-1290OC